96 related articles for article (PubMed ID: 9470845)
1. Frequent detection of mutations in the 5' flanking region of the prostate-specific antigen gene in female breast cancer.
Tsuyuki D; Grass L; Diamandis EP
Eur J Cancer; 1997 Oct; 33(11):1851-4. PubMed ID: 9470845
[TBL] [Abstract][Full Text] [Related]
2. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
Majumdar S; Diamandis EP
Br J Cancer; 1999 Mar; 79(9-10):1594-602. PubMed ID: 10188912
[TBL] [Abstract][Full Text] [Related]
3. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer.
Zarghami N; Grass L; Diamandis EP
Br J Cancer; 1997; 75(4):579-88. PubMed ID: 9052414
[TBL] [Abstract][Full Text] [Related]
4. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours.
Prosser J; Thompson AM; Cranston G; Evans HJ
Oncogene; 1990 Oct; 5(10):1573-9. PubMed ID: 2250913
[TBL] [Abstract][Full Text] [Related]
5. Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
Scorilas A; Bharaj B; Giai M; Diamandis EP
Br J Cancer; 2001 Mar; 84(6):760-7. PubMed ID: 11259089
[TBL] [Abstract][Full Text] [Related]
6. Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer.
Yang QF; Sakurai T; Shan L; Yu Z; Yoshimura G; Suzuma T; Tamaki T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
J Hum Genet; 2000; 45(6):363-6. PubMed ID: 11185746
[TBL] [Abstract][Full Text] [Related]
7. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis of prostate-specific antigen gene sequence in benign and malignant prostate tissue.
Baffa R; Moreno JG; Monne M; Veronese ML; Gomella LG
Urology; 1996 Jun; 47(6):795-800. PubMed ID: 8677566
[TBL] [Abstract][Full Text] [Related]
9. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
[TBL] [Abstract][Full Text] [Related]
10. p53 mutations and overexpression in locally advanced breast cancers.
Faille A; De Cremoux P; Extra JM; Linares G; Espie M; Bourstyn E; De Rocquancourt A; Giacchetti S; Marty M; Calvo F
Br J Cancer; 1994 Jun; 69(6):1145-50. PubMed ID: 8198984
[TBL] [Abstract][Full Text] [Related]
11. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer.
Lehrer S; Terk M; Piccoli SP; Song HK; Lavagnini P; Luderer AA
Br J Cancer; 1996 Sep; 74(6):871-3. PubMed ID: 8826851
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
13. Complex alternative splicing of the hKLK3 gene coding for the tumor marker PSA (prostate-specific-antigen).
Heuzé-Vourc'h N; Leblond V; Courty Y
Eur J Biochem; 2003 Feb; 270(4):706-14. PubMed ID: 12581210
[TBL] [Abstract][Full Text] [Related]
14. p16 mutations/deletions are not frequent events in prostate cancer.
Tamimi Y; Bringuier PP; Smit F; van Bokhoven A; Debruyne FM; Schalken JA
Br J Cancer; 1996 Jul; 74(1):120-2. PubMed ID: 8679444
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors.
Monne M; Croce CM; Yu H; Diamandis EP
Cancer Res; 1994 Dec; 54(24):6344-7. PubMed ID: 7527295
[TBL] [Abstract][Full Text] [Related]
16. Very low PSA concentrations and deletions of the KLK3 gene.
Rodriguez S; Al-Ghamdi OA; Burrows K; Guthrie PA; Lane JA; Davis M; Marsden G; Alharbi KK; Cox A; Hamdy FC; Neal DE; Donovan JL; Day IN
Clin Chem; 2013 Jan; 59(1):234-44. PubMed ID: 23169475
[TBL] [Abstract][Full Text] [Related]
17. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line.
Futreal PA; Cochran C; Marks JR; Iglehart JD; Zimmerman W; Barrett JC; Wiseman RW
Cancer Res; 1994 Apr; 54(7):1791-4. PubMed ID: 7511052
[TBL] [Abstract][Full Text] [Related]
19. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.
Levesque MA; Clark GM; Yu H; Diamandis EP
Br J Cancer; 1995 Sep; 72(3):720-7. PubMed ID: 7545416
[TBL] [Abstract][Full Text] [Related]
20. NOEY2 mutations in primary breast cancers and breast hyperplasia.
Yang J; Hu A; Wang L; Li B; Chen Y; Zhao W; Xu W; Li T
Breast; 2009 Jun; 18(3):197-203. PubMed ID: 19482475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
